尼洛替尼-话题@MedSci

#尼洛替尼#

9篇内容 | 1188人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2195030, encodeId=fbe6219503092, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a> <a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a> <a href='/topic/show?id=260f9e9222d' target=_blank style='color:#2F92EE;'>#阿糖胞苷#</a> <a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴细胞白血病#</a>, objectTitle=【Blood】尼洛替尼+化疗±阿糖胞苷治疗Ph+ ALL的随机研究结果, objectType=article, longId=817874, objectId=775281e874ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-doctor-review-PTX6YZP.jpg, objectUrl=/article/show_article.do?id=775281e874ce, replyNumber=0, likeNumber=110, createdTime=2024-03-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=775281e874ce, moduleTitle=【Blood】尼洛替尼+化疗±阿糖胞苷治疗Ph+ ALL的随机研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=775281e874ce)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1984726, encodeId=60d81984e26ac, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发, objectType=article, longId=736337, objectId=b0e3e36337f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0e3e36337f3, replyNumber=0, likeNumber=108, createdTime=2023-03-28, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0e3e36337f3, moduleTitle=Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0e3e36337f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984725, encodeId=42ae1984e251d, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=JAMA neurology：尼洛替尼对中晚期帕金森患者的疗效, objectType=article, longId=205238, objectId=65c520523821, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65c520523821, replyNumber=0, likeNumber=82, createdTime=2021-01-12, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65c520523821, moduleTitle=JAMA neurology：尼洛替尼对中晚期帕金森患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65c520523821)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984724, encodeId=a3e61984e243e, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=三代“格列卫”同台竞技尼洛替尼又一适应症获批, objectType=article, longId=183424, objectId=2fdc183424d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fdc183424d8, replyNumber=0, likeNumber=101, createdTime=2020-04-22, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fdc183424d8, moduleTitle=三代“格列卫”同台竞技尼洛替尼又一适应症获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fdc183424d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984723, encodeId=a1f41984e238e, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=Blood：尼洛替尼替代伊马替尼治疗Ph+CML-CP儿童患者, objectType=article, longId=179592, objectId=dc5f1e95921f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc5f1e95921f, replyNumber=0, likeNumber=97, createdTime=2020-04-05, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc5f1e95921f, moduleTitle=Blood：尼洛替尼替代伊马替尼治疗Ph+CML-CP儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc5f1e95921f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984722, encodeId=0dc51984e229e, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=Eur J Cancer：尼洛替尼应该被升级为CML一线疗法？, objectType=article, longId=155116, objectId=e350155116fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e350155116fb, replyNumber=0, likeNumber=107, createdTime=2019-04-20, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e350155116fb, moduleTitle=Eur J Cancer：尼洛替尼应该被升级为CML一线疗法？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e350155116fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984720, encodeId=d82f1984e209a, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=Lancet oncol：尼洛替尼（nilotinib），CSF1R酪氨酸激酶抑制剂，可控制色素性绒毛结节性滑膜炎患者的病程进展, objectType=article, longId=133036, objectId=740813303624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=740813303624, replyNumber=0, likeNumber=68, createdTime=2019-01-29, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=740813303624, moduleTitle=Lancet oncol：尼洛替尼（nilotinib），CSF1R酪氨酸激酶抑制剂，可控制色素性绒毛结节性滑膜炎患者的病程进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=740813303624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984721, encodeId=21aa1984e21e8, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=Br J Haematol：CP-CML患者：伊马替尼一线治疗后尼洛替尼怎么样？, objectType=article, longId=141184, objectId=8345141184b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8345141184b7, replyNumber=0, likeNumber=107, createdTime=2019-03-14, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8345141184b7, moduleTitle=Br J Haematol：CP-CML患者：伊马替尼一线治疗后尼洛替尼怎么样？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8345141184b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984719, encodeId=57641984e193d, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=Cancer：倾向评分匹配分析尼洛替尼和达沙替尼治疗慢性期慢性粒细胞白血病, objectType=article, longId=76310, objectId=7223e63103e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7223e63103e, replyNumber=0, likeNumber=84, createdTime=2017-01-04, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7223e63103e, moduleTitle=Cancer：倾向评分匹配分析尼洛替尼和达沙替尼治疗慢性期慢性粒细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7223e63103e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984718, encodeId=06241984e188b, content=<a href='/topic/show?id=7c854e3738a' target=_blank style='color:#2F92EE;'>#尼洛替尼#</a>, objectTitle=诺华称其日本子公司雇员违反尼洛替尼临床研究方案, objectType=article, longId=29662, objectId=90a4296626f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90a4296626f, replyNumber=0, likeNumber=103, createdTime=2014-02-27, rootId=0, userName=1249857fm32暂无昵称, userId=ca282500032, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90a4296626f, moduleTitle=诺华称其日本子公司雇员违反尼洛替尼临床研究方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90a4296626f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

尼洛替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#尼洛替尼# #化疗# #阿糖胞苷# #急性淋巴细胞白血病#

【Blood】尼洛替尼+化疗±阿糖胞苷治疗Ph+ ALL的随机研究结果

2024-03-24发表于上海

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发

2023-03-28

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

JAMA neurology：尼洛替尼对中晚期帕金森患者的疗效

2021-01-12

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

三代“格列卫”同台竞技尼洛替尼又一适应症获批

2020-04-22

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

Blood：尼洛替尼替代伊马替尼治疗Ph+CML-CP儿童患者

2020-04-05

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

Eur J Cancer：尼洛替尼应该被升级为CML一线疗法？

2019-04-20

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

Lancet oncol：尼洛替尼（nilotinib），CSF1R酪氨酸激酶抑制剂，可控制色素性绒毛结节性滑膜炎患者的病程进展

2019-01-29

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

Br J Haematol：CP-CML患者：伊马替尼一线治疗后尼洛替尼怎么样？

2019-03-14

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

Cancer：倾向评分匹配分析尼洛替尼和达沙替尼治疗慢性期慢性粒细胞白血病

2017-01-04

1249857fm32暂无昵称 (审核中...)

前往app查看评论内容

#尼洛替尼#

诺华称其日本子公司雇员违反尼洛替尼临床研究方案

2014-02-27

科室
- - 订阅+
  - 更多科室
工具
服务